FundCanna, a provider of capital to the regulated cannabis industry, has announced it secured a new senior credit facility of up to US$60 million. This financing, provided by a global institutional investment firm with approximately US$40 billion in assets under management, is intended to expand FundCanna’s cannabis funding platform.
The facility provides US$35 million at close, with additional capital available as FundCanna scales its portfolio. In conjunction with this facility, FundCanna is restructuring its broader capital base, which includes new and existing investor participation, bringing its total capital to approximately US$75 million. The company anticipates this new structure will support over US$500 million in cumulative funding across the cannabis industry in the coming years, according to a report by Cannabis Business Times.
Institutional Entry into Cannabis Funding
The transaction represents a notable development for a sector that has historically operated with limited access to institutional credit. While equity and real estate-backed strategies have seen capital inflow, unsecured lending to operating cannabis businesses has largely been absent from institutional portfolios.
“This is institutional capital entering a part of the market it has historically avoided,” said Adam Stettner, founder and CEO of FundCanna. “That includes both established operators and the broader supply chain that drives the cannabis economy. We’ve built our platform to serve the full spectrum of the market, where access to reliable funding has been inconsistent.”
Bryant Park Capital, the investment bank that represented FundCanna in the transaction, highlighted the company’s operational infrastructure and underwriting depth as key factors driving investor interest. Joel Magerman, Managing Partner at Bryant Park Capital, noted that FundCanna’s “real transaction history, risk management discipline and demonstrated capital efficiency” were crucial for attracting institutional participation in a market where such capital has been cautious.
FundCanna’s Operational Model and Market Impact
Since its inception, FundCanna has deployed more than US$250 million in capital, having initially raised approximately US$25 million from private investors. The company has originated over 5,000 transactions and is projected to soon exceed a US$100 million annualized run rate, primarily serving small- and mid-sized operators across the cannabis supply chain.
FundCanna’s model focuses on providing liquidity across the cannabis supply chain, addressing the specific funding needs of multi-state operators, manufacturers, distributors, and retailers. These entities often require specialized financing solutions due to the unique dynamics and regulatory complexities of the cannabis economy.
- Data-Driven Underwriting: The company has invested in data-driven underwriting and automation to navigate the fragmented data and inconsistent laws within the cannabis industry.
- ReadyPaid™ Platform: FundCanna’s ReadyPaid™ Buy Now, Pay Later platform aims to address an estimated US$4 billion in delinquent accounts receivable within the industry. This platform facilitates underwriting decisions in minutes and has processed several million dollars in transactions without reported delinquencies.
With the new facility, FundCanna intends to expand ReadyPaid’s role, particularly among larger multi-state operators and established cannabis brands focused on scaling wholesale distribution. The platform allows sellers to receive upfront payment while offering buyers extended payment flexibility, which can enhance revenue growth, support retail partners, and improve working capital efficiency.
Evolving Landscape for Cannabis Capital
This financing occurs as private credit firms and banks are beginning to re-evaluate the cannabis sector. Evolving regulatory signals and the search for new deployment areas for capital are contributing to early signs of institutional interest, particularly in credit strategies where lenders can price for complexity. FundCanna expects that expanded access to institutional capital will enable increased funding volume and a lower cost of capital over time, broadening access to financing for cannabis operators.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
